Expansion Project of Novo Nordisk’s Tianjin Production Plant Breaks Ground in TEDA

On February 23, Novo Nordisk (China) Pharmaceutical Co., Ltd. held a groundbreaking ceremony for the expansion project of finished product workshop at its Tianjin Production Plant in TEDA. Both the finished product workshop and pre-filled injection pen production line, which is about to start construction, are expected to be invested with about RMB 1.18 billion. This is another big move of Novo Nordisk in Tianjin after investing RMB 500 million in the construction of an elevated stereo warehouse in the fourth quarter of 2022. “Tianjin is the place for Novo Nordisk to set off in China. With the resources of our advanced manufacturing site in Tianjin and this investment, we hope to further expand our high-quality localized production.” said Xiaping Zhou, Senior Vice President of Novo Nordisk Global and President of Greater China.

Novo Nordisk is a leading global biopharmaceutical company headquartered in Denmark. Established in 1995 in TEDA, the Tianjin Production Plant is one of Novo Nordisk’s strategic global manufacturing sites as well as its largest formulation and filling production site worldwide.